Evidence map›Paper›PMID 41135363›Full record

ArticleMolecular pharmacology2025

Distinctive patterns of G protein coupling induced by the structurally similar 5-HT

Patricia Miranda-Azpiazu, Carolina Muguruza, Tomasz Maciej Stepniewski, Itziar Muneta-Arrate, David Moreira, José Brea, Luis F Callado, María Isabel Loza, Javier González-Maeso, Jana Selent and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Patricia Miranda-AzpiazuDepartment of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain.
Carolina MuguruzaDepartment of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain; Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, ISCIII, Spain.
Tomasz Maciej StepniewskiResearch Programme on Biomedical Informatics, Hospital del Mar Research Institute, Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain; InterAx Biotech AG, PARK InnovAARE, Villigen, Switzerland; Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warsaw, Poland.
Itziar Muneta-ArrateDepartment of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain; Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, ISCIII, Spain.
David MoreiraInnopharma Drug Screening and Pharmacogenomics Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain; Kaertor Foundation, Santiago de Compostela, Spain.
José BreaInnopharma Drug Screening and Pharmacogenomics Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Luis F CalladoDepartment of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain; Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, ISCIII, Spain; Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.
María Isabel LozaInnopharma Drug Screening and Pharmacogenomics Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain; Kaertor Foundation, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Javier González-MaesoDepartment of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Jana SelentResearch Programme on Biomedical Informatics, Hospital del Mar Research Institute, Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain.
Rebeca Diez-AlarciaDepartment of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain; Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, ISCIII, Spain; Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.
J Javier MeanaDepartment of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain; Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, ISCIII, Spain; Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. Electronic address: javier.meana@ehu.eus.

Funding

Structure and function of the 5HT2A/mGluR2 complex in schizophreniaR01MH084894 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI Javier Gonzalez-Maeso · 2009 to 2026
$6.8M
NIMH NIH HHS R01 MH084894
6 · The paper itself

Abstract

Antipsychotic activity of certain 5-HT

Indexed as

GTP-Binding ProteinsKetanserinPrefrontal CortexReceptor, Serotonin, 5-HT2AAdultAnimalsFemaleGuanosine 5'-O-(3-Thiotriphosphate)HumansLigandsMaleMiceMiddle AgedMolecular Dynamics SimulationSerotonin 5-HT2 Receptor AntagonistsaltanserinGTP-Binding ProteinsGuanosine 5'-O-(3-Thiotriphosphate)KetanserinLigandsReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor Antagonists5-HT(2A) receptorAntipsychoticBiased agonismFunctional selectivityG proteinInverse agonism

Identifiers

PMID41135363
PMCPMC12799460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.